Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutationMax M. Wattenberg, Kim A. Reiss, Susan M. Domchek et al.|British Journal of Cancer|2019Cited by 206
A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal AdenocarcinomaEugene J. Koay, Jason B. Fleming, Yeon‐Ju Lee et al.|Clinical Cancer Research|2018Cited by 111
Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional StudyKim A. Reiss, David E. Kaplan, Shun Yu et al.|Journal of Clinical Oncology|2017Cited by 98
Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline <i>BRCA</i> or <i>PALB2</i> MutationsKim A. Reiss, Susan M. Domchek, Shun Yu et al.|JCO Precision Oncology|2018Cited by 61
Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline <i>BRCA</i> or <i>PALB2</i> MutationShun Yu, Kim A. Reiss, Ursina Teitelbaum et al.|JCO Precision Oncology|2019Cited by 37